A dose-response clinical trial is a type of clinical trial that investigates the relationship between the dosage of a therapeutic and its effectiveness in patients. North America leads dose-response studies with 43.8% of trials. This region is followed by Asia-Pacific (31.6%), Europe (27.1%), the Middle East and Africa (13.8%) and South and Central America with 0.03%. The top country for dose-response studies was the US, with 41.4% of trials.
When exploring the field of drug development, the US dominates dose-response studies, as US sites and institutions conduct a significant amount of research and have the infrastructure and resources to carry out dose-response studies.
The US has a robust regulatory framework that encourages and supports clinical research, including dose-response studies. Additionally, the US also has a diverse population, which allows for a more comprehensive understanding of how different individuals respond to different doses of medications.
For dose-response trials, Phase I trials outnumbered all other phases with 45.6% of trials. This was followed by Phase II (36.5%), Phase III (10.1%) and then Phase IV with 0.1% of trials. Earlier phases are expected to have higher trial counts in comparison to later phases. Early-phase trials, especially Phase I, focus on evaluating the safety profile of a drug candidate in humans.
Additionally, dose-response trials in the early phases help to find the right dose for patients. Early-phase trials are typically conducted with a relatively small number of
subjects, making them more manageable and cost-effective than the larger trials in later phases.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form